The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with metronidazole for patients 18 years and older who have limited or no alternative options for the ...

艾伯维（AbbVie）公司今日（2月8日）宣布，美国FDA已批准该公司与辉瑞（Pfizer）联合开发的Emblaveo（aztreonam和avibactam）上市，与甲硝唑联合使用 ...

AbbVie announced that the US Food and Drug Administration (FDA) has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/ß-lactamase inhibitor ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo (aztreonam-avibactam) to treat complicated intra-abdominal infections, including those ...

艾伯维公司（ABBV）股价创下重要里程碑，达到历史最高点207.34美元。这家市值3,650亿美元、年收入超过560亿美元的制药巨头继续展示其市场主导地位。根据 InvestingPro 分析，该股票的相对强弱指数（RSI）显示处于超买区域，提示投资者需谨慎选择入场时机。这一新高反映了过去一年的强劲表现，该制药巨头股价增长了17.45%。公司的盘坚地位进一步得到巩固，这得益于其连续12年提高股息的 ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...